Harrow (Harrow) Cash Flow from Financing : $126.5 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Harrow Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Harrow paid $0.0 Mil more to buy back shares than it received from issuing new shares. It received $0.0 Mil from issuing more debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It received $0.0 Mil on other financial activities. In all, Harrow spent $0.0 Mil on financial activities for the three months ended in Dec. 2023.

Harrow Cash Flow from Financing Historical Data

The historical data trend for Harrow's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Cash Flow from Financing Chart

Harrow Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

-1.01

1.43

51.47

54.14

126.53

Harrow Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Financing	Get a 7-Day Free Trial															55.03	62.16	0.19	64.20	-0.02

Harrow Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Harrow's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	64.52	+	0	+	74.642	+	0	+	0	+	-12.634
=	126.5

Harrow's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.0

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $126.5 Mil.

Harrow (NAS:HROW) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Harrow's issuance of stock for the three months ended in Dec. 2023 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Harrow's repurchase of stock for the three months ended in Dec. 2023 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Harrow's net issuance of debt for the three months ended in Dec. 2023 was $0.0 Mil. Harrow received $0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Harrow's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. Harrow paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Harrow's cash flow for dividends for the three months ended in Dec. 2023 was $0.0 Mil. Harrow received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Harrow's other financing for the three months ended in Dec. 2023 was $0.0 Mil. Harrow received $0.0 Mil on other financial activities.

Harrow Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Harrow's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Harrow (Harrow) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205

Website

https://www.harrow.com

Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.

Executives

Mark L Baum	director, 10 percent owner, officer: Chief Executive Officer	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence	director	354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll	officer: VP, Accounting and Reporting	437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks	director	40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer	director, 10 percent owner, officer: Chairman of the Board	1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc	other: Institutional Investor	9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad	other: Managing Mbr of Longboard Cap.	1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards	officer: Chief Operating Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi	director	2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni	10 percent owner	1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek	officer: Chief Commercial Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130